Drug Profile
Neostigmine - Exela Sterile Medicines
Alternative Names: Bloxiverz; Neostigmine methylsulfateLatest Information Update: 27 Oct 2021
Price :
$50
*
At a glance
- Originator Eclat Pharmaceuticals
- Developer Avadel Pharmaceuticals
- Class Antiglaucomas; Quaternary ammonium compounds
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neuromuscular blockade
Most Recent Events
- 01 Jul 2020 Exela Sterile Medicines acquires neostigmine from Avadel Pharmaceuticals
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
- 29 Jul 2013 Launched for Neuromuscular blockade in USA (IV) - first global launch